Transforming Patient Care by Unlocking Challenging Targets

March Biosciences is a clinical-stage company in the cell therapy field focused on developing CAR-T cell strategies accross hematological cancers, indications with limited therapeutic options

Addressing Key Challenges
in Cell Therapy

Target Space

Our approaches combine biological and engineering insights to enable target-unlock without the risk and complexity of additional gene editing.

Cell Quality

By minimizing cell manipulation and intensely focusing on cell quality during production, our team is dedicated to ensuring the underlying engine of our cell therapies achieves peak function.


We assembled a team of technical development and cell therapy specialists to ensure the robust and efficient production of high-quality CAR-T cells.

Our Mission

We are dedicated to revolutionizing patient care by unlocking new targets for challenging indications. To meet this goal, we have developed a team of innovators possessing extensive drug development experience and highly specialized in the cell therapy field

Our First Product

MB-105 is designed to drive impact in  highly unmet clinical needs, T- cell lymphoma:

10-20% Of Patients

with relapsed / refractory T-cell lymphoma will survive 3 years

Narrow therapeutic options

leave patients with reduced chances of positive outcomes

Limited drug development

for on-target, off-tumor toxicity
Play Video

Our Team

We have a deep, seasoned leadership team with more than 20 years of experience in the cell therapy field.

News & Publications

Read more about how March Biosciences’ research has impacted the medical community.